Mounjaro vs Wegovy UK Cost 2026: Which Is Better Value?

The head-to-head clinical data is now in. The 2025 SURMOUNT-5 trial compared tirzepatide (Mounjaro) directly against semaglutide (Wegovy) in a randomised controlled trial. Mounjaro produced 20.2% mean weight loss versus 13.7% for Wegovy - a statistically significant difference that changes the clinical calculation for most patients.

But Mounjaro runs slightly more expensive at maintenance doses, and the 12-month cost difference is not negligible. This guide works through the full cost comparison - starter, escalation, and maintenance - and answers whether Mounjaro's superior efficacy justifies the price difference.

---

The Clinical Case: Does Mounjaro Win?

Before the cost analysis, the efficacy question deserves a direct answer.

Mounjaro's efficacy advantage in SURMOUNT-5 (6.5 percentage points of additional weight loss) is clinically meaningful. For a 100kg person, the difference between 13.7% and 20.2% loss is roughly 6.5kg - the difference between meaningful weight reduction and transformative results.

The caveat: these are population averages. Some patients do exceptionally well on Wegovy. Individual response varies based on genetics, lifestyle, comorbidities, and adherence. You cannot predict in advance whether you will be a Wegovy high-responder or whether you need tirzepatide's dual GIP/GLP-1 mechanism to achieve comparable results.

There is also the new Wegovy 7.2mg formulation, MHRA-approved in January 2026, which achieved 20.7% mean weight loss in its pivotal trial - narrowing the gap considerably. This formulation is starting to become available but is not yet universally stocked across UK providers.

---

Monthly Cost: Dose by Dose

Mounjaro vs Wegovy - Click Pharmacy Pricing

Click Pharmacy pricing, May 2026. Verify directly. Prices change.

Mounjaro vs Wegovy - Pharmacy2U Pricing

Pharmacy2U pricing, May 2026. Verify directly.

---

12-Month Total Cost Comparison

Assuming standard titration (4 weeks at each dose, reaching maintenance dose at month 5–6 and staying there):

Wegovy 12-month total (Click Pharmacy):

• Months 1–4: £139 + £149 + £169 + £189 = £646
• Month 5: £209
• Months 6–12: £209 x 7 = £1,463
• Total: approximately £2,318

Mounjaro 12-month total (Click Pharmacy):

• Months 1–5: £139 + £159 + £179 + £199 + £219 = £895
• Months 6–12: £239 x 7 = £1,673
• Total: approximately £2,568

Difference: approximately £250 more for Mounjaro over 12 months, using the cheapest UK provider for both.

---

Is the £250 Difference Worth It?

This is the central question, and it depends on how you value the clinical data.

For a 100kg patient starting treatment:

• Wegovy at 13.7% = ~13.7kg lost
• Mounjaro at 20.2% = ~20.2kg lost
• Additional weight loss from Mounjaro: ~6.5kg

Cost per additional kilogram lost from choosing Mounjaro: roughly £38 per extra kilogram of weight loss over 12 months.

Whether that represents good value is a personal calculation. For most patients who are significantly overweight and for whom the difference between 13.7% and 20.2% loss is meaningful for their health outcomes, cardiometabolic risk, or quality of life - £250 extra over a year is unlikely to be the deciding factor.

---

When Wegovy Is the Better Choice

Despite the SURMOUNT-5 data, Wegovy remains the right choice in several situations:

You have a contraindication to tirzepatide: Both drugs share most contraindications, but individual patients may have specific reasons a prescriber chooses semaglutide.

You are already on semaglutide and responding well: If you are currently on Wegovy and achieving good results, switching for a marginal potential benefit introduces unnecessary disruption.

The new 7.2mg formulation is available: Wegovy 7.2mg (MHRA-approved January 2026) achieved 20.7% mean weight loss in its trial - statistically comparable to Mounjaro's 20.9% from SURMOUNT-1. If your provider can access this formulation, the efficacy argument for Mounjaro weakens significantly.

Supply issues with Mounjaro in your area: Mounjaro supply has been intermittent at higher doses. If your local supply chain is unreliable, Wegovy's more established supply infrastructure may be preferable.

---

When Mounjaro Is the Better Choice

Mounjaro is the stronger clinical choice for most treatment-naive patients when:

You are starting fresh with no prior GLP-1 exposure: If you have never taken a GLP-1 medication, the head-to-head data from SURMOUNT-5 supports tirzepatide as first choice.

You have significant weight to lose: The greater absolute weight loss from Mounjaro has larger absolute health implications at higher starting weights.

You have type 2 diabetes or pre-diabetes: Tirzepatide's dual GIP/GLP-1 mechanism provides superior glycaemic control in addition to weight loss, which is particularly relevant if blood sugar management is a concurrent goal.

The cost difference is manageable: At starter doses, there is no cost difference. The premium only materialises at maintenance doses.

For more clinical detail on both medications, see our Mounjaro UK guide.

---

How to Access Either Medication

Both Mounjaro and Wegovy are available through several UK online prescribers. The two most competitively priced are Pharmacy2U and Click Pharmacy.

For the full market comparison including all major UK providers, see our best GLP-1 prescribers UK guide. If cost is your primary concern, our cheapest GLP-1 prescription UK guide covers the full pricing landscape.

---

Supply and Availability

Both medications have experienced supply shortages as demand has outpaced manufacturing capacity. The current position:

Mounjaro: Generally well-supplied at lower doses. Occasional shortages at 10mg, 12.5mg, and 15mg. Check with your provider before prescribing.

Wegovy: Supply has improved significantly since 2024. The new 7.2mg formulation is in limited supply as it rolls out.

Ozempic: Often confused with Wegovy - different dose formulation, primarily a diabetes medication. Supply shortages in Ozempic can affect people with type 2 diabetes who depend on it. Do not choose Ozempic over Wegovy for weight management.

---

Frequently Asked Questions

Can I start on Wegovy and switch to Mounjaro later? Yes. Switching between GLP-1 medications requires a new prescription and a prescriber review. You would typically restart at the lowest dose of the new medication and re-escalate. Some patients who do not respond adequately to semaglutide have good outcomes after switching to tirzepatide.

Are there generic versions available in the UK? Not for these branded formulations. Compounded semaglutide is available from unlicensed sources, but the MHRA has issued warnings about unregulated compounded GLP-1 products. Stick to licensed medications.

Does insurance cover either medication? Private health insurance in the UK very rarely covers weight management medications. This is an out-of-pocket cost for the vast majority of patients.

Will the prices drop over time? Eli Lilly and Novo Nordisk have both signalled plans to expand global manufacturing capacity. As supply increases and potential generic competition emerges post-patent, prices may decrease. This is speculative, and current pricing reflects a high-demand market.

What about NHS cost? Both Mounjaro and Wegovy are available on the NHS at no prescription charge, but access is through specialist weight management services with strict criteria and long waiting lists. For most patients, private prescription is the realistic pathway. See our NHS GLP-1 eligibility guide for full details.